Noga Therapeutics


Embark on a journey with us to transform healthcare

Join our mission to redefine medical boundaries. We seek visionary scientists eager to make a lasting impact in health innovation.

Current open positions:

We are looking for a motivated scientist to join the team as a research scientist. The successful candidate will play a major role in helping design and develop a product candidate from early discovery phases through IND enabling studies. This is a great opportunity to take part in creatinga novel gene therapy modalityin a growing and dynamic start-up.


  • Execute and support experiments using cell culture and molecular biology methodologies.
  • Write protocols and SOPs according to industry practice.
  • Manage and maintain lab stocks and inventory.
  • Compile and present research data to internal teams


  • MSc or PhD in molecular biology, cell biology, or related fields.
  • Hands-on research experience, including cloning and cell culture techniques.
  • Team player.
  • Ability to work independently.

Please submit your resume to

We are looking for a motivated PhD level Scientist to play a crucial leadership part in our core vector development team. If you seek a meaningful Job and relish the opportunity to shape the future of a young yet rapidly expanding start-up – this might be your opportunity.
The successful candidate will lead our efforts to develop and test a lentiviral vector for our Parkinson’s program.
The position requires adaptability, creativity, and a capacity for constant innovation in pursuit of company goals. The environment is exciting and fast-paced and offers the opportunity to work at the cutting edge of gene therapy research.


  • Design and construct a set of candidate lentiviral vectors.
  • Develop cell based and molecular biology assays for lead vector selection.
  • Conceive, design, and perform experiments independently.
  • Managed and coordinated third-party collaborators and CROs.
  • Mentor junior stuff members in laboratory research and techniques.
  • Keep abreast of new scientific/technology development by participating in scientific meetings and through regular scientific review.
  • Present all aspects of work to team, executive management, and outside collaborators.

Who should apply - Essential (must-have):

  • Ph.D. degree in molecular biology, cell biology, immunology, or related field
  • Hands-on research experience, including cell culture techniques.
  • Understanding of hematopoietic stem cell biology
  • Experience in assay development, calibration, and troubleshooting.
  • Excellent scientific writing and oral communication skills

Preferred (nice -to-have):

  • Drug discovery or pre-clinical development expertise.
  • Experience with cloning techniques, including Gibson assembly.
  • Extensive knowledge in gene or cell therapy.
  • Bioinformatics and data analysis skills.
  • Industry experience.

For more information and to apply contact, please refer to the title of the position in your application.

Sefi Golan


Sefi is a 22-year entrepreneur who founded a Nasdaq-listed company. He has a proven track record of assembling exceptional teams and building technology ahead of its time.
Sefi founded HUB Cyber Security, which reached a peak market capitalization of $350 million. He also advised Bancor, which raised $153 million and reached a peak market capitalization of $800 million.
Currently Sefi is heading the investment team in a privately owned family office.
Sefi holds a B.Sc. in Business Administration and Economics from the University of Tel Aviv.

Adam Brian

Head of Personalized Medicine at Lonza

Mr.  Adam Brian heads Lonza Personalized Medicine, which focuses on developing and bringing to market tools that enable research and development, scale out, and commercialization of patient scale cell therapies, with an emphasis on decentralized and point of care manufacturing. Mr. Brian  is a results-oriented leader with extensive experience in the life science and medical device industries. Proven track record of increasing revenue, improving operations, and building and leading high-performing teams. 

Dr. Eytan Abraham

VP, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience

 Dr. Eytan Abraham heads Resilience cell, gene and nucleic acids Franchises. Dr. Abraham holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell-therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School. Dr. Abraham is an experienced scientist and business leader with expertise in basic and applied biological and cell therapy R&D as well as in management, technology, and commercialization.

Anat Naschitz

CEO and Co-Founder - 9xchange

Anat Naschitz is a lifescience investor and entrepreneur, with 27 years of experience across biotech, pharma, digital health and medical devices. 

Anat co-founded and co-led OrbiMed Israel, an Israel focused VC fund and part of the leading, $20bn global healthcare investment firm, and was previously with Apax, the €60bn private equity firm, where she started her investment career. Previously Anat was an Associate Partner with McKinsey in London, where she advised the world’s preeminent pharmaceutical companies on strategy, acquisitions and spinouts.

Throughout her career Anat has founded companies and nurtured them through success. Examples include 89bio (Nasdaq:ETNB), developing a likely best in class therapeutic for NASH, which she co-founded and spun out of Teva, taking it public on Nasdaq 18 months post creation, currently trading at $1bn; Sobi, which evolved out of a Pharmacia spinout and currently trading at $7.4bn; and many others. 

Currently, Anat is co-founder and CEO of 9xchange, a biopharma marketplace, creating transparency and enabling the ecosystem to monetize pipelines and discover assets whose availability was unknown, through a seamless, initially anonymous, AI-driven process. 

Anat earned her MBA at Insead in France and her LLB at Tel Aviv University.

Dr. Yael Weiss

CEO - Mahzi Therapeutics

Dr. Yeal Weiss is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Dr. Weiss completed her MD at Hadassah Medical School at the Hebrew University in Jerusalem and her PhD at the Weizmann Institute of Science in Rehovot, Israel. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx. Dr. Weiss is a member of the NIH driven Bespoke Gene Therapy (BCTG) consortium, ASGCT translational committee, N=1 collaborative and is a 2022 Termeer Fellow. Board member/advisor to ADNP and FOXG1 foundations.

Noam Baumatz


Noam is a physician with 20 years of experience in the field of complementary medicine (Brighton University). He formerly headed the Chinese Medicine Unit at Sheba Hospital. Noam is the founder and CEO of the Association for Noga (Her Way), which develops advanced therapies for ultra-rare diseases.

Dr. Liron Elkouby

Scientific Advisor

Liron brings many years of experience in cell- and gene-therapy translation. Prior to joining NOGA Therapeutics, Liron headed the discovery and the early-phase development of oncology at Enlivex Therapeutics. Prior to that, Liron led the hemophilia A program (currently in phase III) at Spark Therapeutics, USA. Liron holds a PhD from and conducted postdoctoral research at the Technion.

Dr. Noam Diamant


Noam previously co-founded Emendo Biotherapeutics, a leading CRISPR company that was acquired by Anges, Japan, in 2020, for $295M. As an expert on intellectual property strategies at Ingenium IP, Noam advised dozens of biomed companies on building their IP-business strategy. Noam holds a PhD from the Weizmann Institute of Science in the field of DNA damage repair.